ArticleAngewandte Chemie (International ed. in English)2025
Unnatural Triggers Converted From Tetrazine-Attached Sialic Acid for Activation of Optoacoustic Imaging-Guided Cancer Theranostics.
Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precise and rapid release of X-ray activated autophagy inhibitors for radiotherapy sensitization of hypopharyngeal carcinoma.Materials today. Bio · 2026Article
- Spatiotemporally Controlled Bioorthogonal Prodrug Activation for Precise Chemotherapy.Small science · 2026Article
- Unnatural Triggers Converted From Tetrazine-Attached Sialic Acid for Activation of Optoacoustic Imaging-Guided Cancer Theranostics.Angewandte Chemie (International ed. in English) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Constructing chemical groups on cell membranes through metabolic glycoengineering of unnatural sugars is an effective means to solve the issue of insufficient or even lack of targets in cancer theranostics. Herein, we address the limitations by developing a tetrazine precursor (SiaTz) based on a nonO-acetylated sialic acid scaffold and then utilizing it to create unnatural tetrazine triggers on the surface of cancer cells. SiaTz exhibits a good balance between the stability and reaction kinetics under physiological conditions and can be efficiently converted into corresponding tetrazine trigger through bypassing several size-limiting steps in metabolic glycoengineering process. We also prepare a proof-of-concept theranostic combination of a trans-cyclooctene derivative (CyTCO) and a thermal-sensitive drug 2,2'-azobis[2-(2-imidazolin-2-yl) propane]-dihydrochloride (AIPH) to verify the activation function of tetrazine triggers in theranostics of orthotopic and metastatic tumors. In the presence of tetrazine triggers, CyTCO can be activated via bio-orthogonal reaction to induce optoacoustic signal enhancement, enabling high-contrast diagnostic imaging and precise tumor localization to guide subsequent treatments. Tetrazine trigger-activated CyTCO displays high photo-to-heat conversion efficiency, which can cause an obvious increase in temperature under laser irradiation and then initiate AIPH decomposition to produce toxic radicals for combined therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.